Skip to main content
Journal cover image

Successful use of amphotericin B lipid complex in the treatment of cryptococcosis.

Publication ,  Journal Article
Baddour, LM; Perfect, JR; Ostrosky-Zeichner, L
Published in: Clin Infect Dis
May 1, 2005

The efficacy and renal safety of amphotericin B lipid complex (ABLC) injection were assessed in 106 patients with cryptococcal infection. Eighty-three patients (78%) had a central nervous system (CNS) infection. Of these patients, 20 initiated azole therapy concomitantly with ABLC therapy, and 7 had received prior azole therapy, which continued during administration of ABLC. Clinical response (cured or improved) was achieved in 67 (66%) of 101 patients whose results could be evaluated. Response rates were 65% (51/78) for patients with a CNS infection and 70% (16/23) for patients without a CNS infection. The response rate for patients with HIV infection was 58% (30/52). Response rates were 56% (19/34) for patients who were refractory to prior antifungal therapy, 65% (11/17) for patients who were intolerant of prior antifungal therapy, 60% (3/5) for patients with underlying renal disease who received prior antifungal therapy, 76% (25/33) for patients with underlying renal disease who did not receive prior antifungal therapy, and 73% (8/11) for patients with no renal disease who did not receive prior antifungal therapy. A mean serum creatinine level decrease of 0.02 mg/dL occurred. ABLC was an effective treatment for cryptococcal infection in immunocompromised patients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

May 1, 2005

Volume

40 Suppl 6

Start / End Page

S409 / S413

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Registries
  • Phosphatidylglycerols
  • Phosphatidylcholines
  • Opportunistic Infections
  • Microbiology
  • Male
  • Immunocompromised Host
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Baddour, L. M., Perfect, J. R., & Ostrosky-Zeichner, L. (2005). Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin Infect Dis, 40 Suppl 6, S409–S413. https://doi.org/10.1086/429337
Baddour, Larry M., John R. Perfect, and Luis Ostrosky-Zeichner. “Successful use of amphotericin B lipid complex in the treatment of cryptococcosis.Clin Infect Dis 40 Suppl 6 (May 1, 2005): S409–13. https://doi.org/10.1086/429337.
Baddour LM, Perfect JR, Ostrosky-Zeichner L. Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin Infect Dis. 2005 May 1;40 Suppl 6:S409–13.
Baddour, Larry M., et al. “Successful use of amphotericin B lipid complex in the treatment of cryptococcosis.Clin Infect Dis, vol. 40 Suppl 6, May 2005, pp. S409–13. Pubmed, doi:10.1086/429337.
Baddour LM, Perfect JR, Ostrosky-Zeichner L. Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin Infect Dis. 2005 May 1;40 Suppl 6:S409–S413.
Journal cover image

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

May 1, 2005

Volume

40 Suppl 6

Start / End Page

S409 / S413

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Registries
  • Phosphatidylglycerols
  • Phosphatidylcholines
  • Opportunistic Infections
  • Microbiology
  • Male
  • Immunocompromised Host
  • Humans
  • Female